Ajanta Pharma Limited (NSE:AJANTPHARM)
India
· Delayed Price · Currency is INR 2,569.50
-4.00 (-0.16%)
May 23, 2025, 3:29 PM IST
Ajanta Pharma Revenue
In the fiscal year ending March 31, 2025, Ajanta Pharma had annual revenue of 46.48B INR with 10.44% growth. Ajanta Pharma had revenue of 11.70B in the quarter ending March 31, 2025, with 11.04% growth.
Revenue
46.48B
Revenue Growth
+10.44%
P/S Ratio
6.91
Revenue / Employee
5.76M
Employees
8,073
Market Cap
321.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 46.48B | 4.39B | 10.44% |
| Mar 31, 2024 | 42.09B | 4.66B | 12.45% |
| Mar 31, 2023 | 37.43B | 4.02B | 12.02% |
| Mar 31, 2022 | 33.41B | 4.51B | 15.62% |
| Mar 31, 2021 | 28.90B | 3.02B | 11.66% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 545.43B |
| Divi's Laboratories | 93.60B |
| Cipla | 271.45B |
| Mankind Pharma | 122.07B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Ajanta Pharma News
- 23 days ago - Ajanta Pharma Q4 Results: Net profit grows 11% YoY to Rs 225 crore, EBITDA Margin at 25% - Business Upturn
- 5 weeks ago - Stocks to buy today on brokerages’ call: IndiGo, Ajanta Pharma, TBO, HDFC Bank, Vodafone Idea among top picks – Check investment target - Business Upturn
- 5 weeks ago - Jefferies initiates Buy on Ajanta Pharma, sees 11% upside due to strong presence in branded generics markets - Business Upturn
- 5 weeks ago - Stocks to watch today: Interglobe Aviation, Ajanta Pharma, HDFC Bank, Vodafone Idea, Hindalco, TBO, L&T in focus on brokerage reports - Business Upturn
- 4 months ago - Ajanta Pharma Q3FY25 results: Revenue rises 4% YoY to Rs 1,146 crore, PAT Up 11% to Rs 233 crore - Business Upturn
- 6 months ago - Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27% - Business Upturn
- 7 months ago - Ajanta Pharma declares first interim dividend of ₹28 per share for FY25 - Business Upturn
- 7 months ago - Ajanta Pharma Q2 FY25 Results: Revenue rises 15% to ₹1,187 crore, net profit grows 11% to ₹216 crore - Business Upturn